Comparative Pharmacology
Head-to-head clinical analysis: INVEGA SUSTENNA versus ZYPREXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVEGA SUSTENNA versus ZYPREXA.
INVEGA SUSTENNA vs ZYPREXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paliperidone is an atypical antipsychotic that acts primarily as a central dopamine type 2 (D2) receptor antagonist and serotonin type 2A (5-HT2A) receptor antagonist. It also blocks α1- and α2-adrenergic receptors and H1 histamine receptors.
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic M1 receptors.
Initiate with 234 mg intramuscular injection on day 1, then 156 mg on day 8, both deltoid. Maintenance: 117 mg monthly (range 39-234 mg) via deltoid or gluteal injection. Dosing based on paliperidone palmitate.
5-10 mg orally once daily; may increase by 5 mg/day at intervals of at least 1 week; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life ranges from 25 to 49 days (mean ~38 days) for deltoid injection and 30 to 50 days (mean ~45 days) for gluteal injection, supporting monthly dosing.
Terminal elimination half-life ~30 hours (range 21–54 h) in adults, allowing once-daily dosing; steady-state reached in ~5–7 days. Half-life prolonged in elderly, females, and hepatic impairment.
Renal: approximately 59-80% as unchanged drug and metabolites, with about 1% unchanged; biliary/fecal: approximately 20-41% primarily as metabolites.
Primarily hepatic metabolism via CYP1A2 and CYP2D6; ~7% excreted unchanged in urine, ~57% in urine as metabolites, ~30% in feces (mostly metabolites).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic